Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

TP53 aberrant Mantle Cell Lymphoma treated with first-line systemic therapy: A real-world analysis of outcomes in 120 patients treated in the United Kingdom

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRory McCullochVVVaishak VidyadharGPGavin Preston

Discussion

Loading...

Member takes

Overview

Retrospective analysis assesses overall survival in 120 patients with TP53 aberrant Mantle Cell Lymphoma, suggesting limitations of current treatment approaches.

Key Points

  • Median overall survival for patients was 29.8 months, indicating suboptimal management strategies for TP53 aberrant MCL.
  • Among patients treated, 68% achieved a complete response with overall systemic therapy showing promising initial results.
  • Retrospective analysis of anonymized data from 120 patients revealed factors like LDH ratio >1.5 predictive of survival outcomes.
  • Urgent need for novel strategies highlighted due to poor durability of responses to initial therapy and challenges in delivering second-line treatments.

Cite This Study

McCulloch et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d470https://doi.org/10.1182/blood-2025-1827
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biallelic TP53 alterations predict poorer survival in Mantle Cell Lymphoma: Insights from a national real-world cohort high-touch project2025
  2. 2Real-world treatment and outcomes of Mantle Cell Lymphoma in Latin America: A multinational cohort analysis2025
  3. 3Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States2025
  4. 4Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis2025
  5. 5Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study2025 · 1 citations